Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 21

1.

No Evidence That HIV-1 Subtype C Infection Compromises the Efficacy of Tenofovir-Containing Regimens: Cohort Study in the United Kingdom.

White E, Smit E, Churchill D, Collins S, Booth C, Tostevin A, Sabin C, Pillay D, Dunn DT; UK HIV Drug Resistance Database and UK Collaborative HIV Cohort Study.

J Infect Dis. 2016 Nov 1;214(9):1302-1308. Epub 2016 May 24.

2.

Mortality of treated HIV-1 positive individuals according to viral subtype in Europe and Canada: collaborative cohort analysis.

Antiretroviral Therapy Cohort Collaboration (ART-CC); Canadian Observational Cohort Collaboration (CANOC); UK Collaborative HIV Cohort Study (UK CHIC); Collaboration of Observational HIV Epidemiological Research in Europe (COHERE).

AIDS. 2016 Jan 28;30(3):503-13. doi: 10.1097/QAD.0000000000000941.

3.

Host, disease, and antiretroviral factors are associated with normalization of the CD4:CD8 ratio after initiating antiretroviral therapy.

Winston A, Jose S, Fisher M, Walsh J, Nelson M, Gilson R, Post F, Johnson M, Leen C, Chadwick D, Hay P, Pritchard J, Tariq A, Sabin C; UK Collaborative HIV Cohort Study.

J Allergy Clin Immunol. 2015 Dec;136(6):1682-5.e1. doi: 10.1016/j.jaci.2015.05.047. Epub 2015 Aug 4. No abstract available.

PMID:
26253341
4.

Incomplete reversibility of estimated glomerular filtration rate decline following tenofovir disoproxil fumarate exposure.

Jose S, Hamzah L, Campbell LJ, Hill T, Fisher M, Leen C, Gilson R, Walsh J, Nelson M, Hay P, Johnson M, Chadwick D, Nitsch D, Jones R, Sabin CA, Post FA; UK Collaborative HIV Cohort Study Steering Committee.

J Infect Dis. 2014 Aug 1;210(3):363-73. doi: 10.1093/infdis/jiu107. Epub 2014 Feb 28.

5.

The effects of age on associations between markers of HIV progression and markers of metabolic function including albumin, haemoglobin and lipid concentrations.

Samuel M, Jose S, Winston A, Nelson M, Johnson M, Chadwick D, Fisher M, Leen C, Gompels M, Gilson R, Post FA, Hay P, Sabin CA; UK Collaborative HIV Cohort Study.

HIV Med. 2014 May;15(5):311-6. doi: 10.1111/hiv.12103. Epub 2013 Nov 19.

6.

HLA B*5701 status, disease progression, and response to antiretroviral therapy.

UK Collaborative HIV Cohort Study Steering Committee.

AIDS. 2013 Oct 23;27(16):2587-92. doi: 10.1097/01.aids.0000432613.95455.71.

7.

Low frequency of genotypic resistance in HIV-1-infected patients failing an atazanavir-containing regimen: a clinical cohort study.

Dolling DI, Dunn DT, Sutherland KA, Pillay D, Mbisa JL, Parry CM, Post FA, Sabin CA, Cane PA; UK HIV Drug Resistance Database (UKHDRD); UK Collaborative HIV Cohort Study (UK CHIC).

J Antimicrob Chemother. 2013 Oct;68(10):2339-43. doi: 10.1093/jac/dkt199. Epub 2013 May 27.

8.

Effects of age on antiretroviral plasma drug concentration in HIV-infected subjects undergoing routine therapeutic drug monitoring.

Winston A, Jose S, Gibbons S, Back D, Stohr W, Post F, Fisher M, Gazzard B, Nelson M, Gilson R, Orkin C, Johnson M, Palfreeman A, Chadwick D, Leen C, Schwenk A, Anderson J, Gompels M, Dunn D, Khoo S, Sabin C; UK Collaborative HIV Cohort Study.

J Antimicrob Chemother. 2013 Jun;68(6):1354-9. doi: 10.1093/jac/dkt029. Epub 2013 Feb 23.

PMID:
23435690
9.

Aspartate aminotransferase-to-platelet ratio index is a powerful predictor of mortality among HIV-positive patients.

Post FA, Sabin CA; UK Collaborative HIV Cohort Study Steering Committee.

J Infect Dis. 2013 Jan 15;207(2):367-8. doi: 10.1093/infdis/jis666. Epub 2012 Oct 29. No abstract available.

PMID:
23107784
10.

HIV-1 subtype and virological response to antiretroviral therapy: a confirmatory analysis.

Dolling DI, Dunn DT, Geretti AM, Sabin CA; UK HIV Drug Resistance Database and UK Collaborative HIV Cohort Study.

Clin Infect Dis. 2013 Jan;56(1):162-3. doi: 10.1093/cid/cis884. Epub 2012 Oct 16. No abstract available.

PMID:
23074305
11.

Biomarkers to monitor safety in people on art and risk of mortality.

Bansi L, Gazzard B, Post F, Phillips A, Johnson M, Hill T, Gilson R, Leen C, Walsh J, Fisher M, Sabin C; UK Collaborative HIV Cohort Study.

J Acquir Immune Defic Syndr. 2012 May 1;60(1):51-8. doi: 10.1097/QAI.0b013e31824d2134.

PMID:
22330610
12.

The effect of transmitted HIV-1 drug resistance on pre-therapy viral load.

Harrison L, Castro H, Cane P, Pillay D, Booth C, Phillips A, Geretti AM, Dunn D; UK Collaborative Group on HIV Drug Resistance and the UK Collaborative HIV Cohort Study (UK CHIC).

AIDS. 2010 Jul 31;24(12):1917-22. doi: 10.1097/QAD.0b013e32833c1d93.

PMID:
20588166
13.

Positive and negative drug selection pressures on the N348I connection domain mutation: new insights from in vivo data.

Price H, Asboe D, Pozniak A, Gazzard B, Fearnhill E, Pillay D, Dunn D; UK Collaborative Group on HIV Drug Resistance; UK Collaborative HIV Cohort Study.

Antivir Ther. 2010;15(2):203-11. doi: 10.3851/IMP1511.

PMID:
20386075
14.

Data linkage reduces loss to follow-up in an observational HIV cohort study.

Hill T, Bansi L, Sabin C, Phillips A, Dunn D, Anderson J, Easterbrook P, Fisher M, Gazzard B, Gilson R, Johnson M, Leen C, Orkin C, Schwenk A, Walsh J, Winston A, Babiker A, Delpech V; UK Collaborative HIV Cohort Study Group.

J Clin Epidemiol. 2010 Oct;63(10):1101-9. doi: 10.1016/j.jclinepi.2009.12.007. Epub 2010 Mar 29.

PMID:
20347263
15.

Discordant responses on starting highly active antiretroviral therapy: suboptimal CD4 increases despite early viral suppression in the UK Collaborative HIV Cohort (UK CHIC) Study.

Gilson RJ, Man SL, Copas A, Rider A, Forsyth S, Hill T, Bansi L, Porter K, Gazzard B, Orkin C, Pillay D, Schwenk A, Johnson M, Easterbook P, Walsh J, Fisher M, Leen C, Anderson J, Sabin CA; UK Collaborative HIV Cohort Study Group.

HIV Med. 2010 Feb;11(2):152-60. doi: 10.1111/j.1468-1293.2009.00755.x. Epub 2009 Sep 1.

16.

Virological response to initial antiretroviral regimens containing abacavir or tenofovir.

Bansi L, Sabin C, Gilson R, Gazzard B, Leen C, Anderson J, Dunn D, Hill T, Fisher M, Ainsworth J, Pillay D, Johnson M, Walsh J, Orkin C, Easterbrook P, Gompels M, Phillips A; UK Collaborative HIV Cohort Study.

J Infect Dis. 2009 Sep 1;200(5):710-4. doi: 10.1086/605024.

PMID:
19635022
17.

Is 1 alanine transaminase >200 IU enough to define an alanine transaminase flare in HIV-infected populations? A new definition derived from a large cohort study.

Bansi L, Turner J, Gilson R, Post F, Gazzard B, Leen C, Anderson J, Porter K, Hill T, Fisher M, Ainsworth J, Pillay D, Johnson M, Winston A, Orkin C, Easterbrook P, Phillips A, Sabin C; UK Collaborative HIV Cohort Study.

J Acquir Immune Defic Syndr. 2009 Nov 1;52(3):391-6. doi: 10.1097/QAI.0b013e3181ab73cc.

PMID:
19553826
18.

Population trends in the prevalence and patterns of protease resistance related to exposure to unboosted and boosted protease inhibitors.

Dunn D, Geretti AM, Green H, Fearnhill E, Pozniak A, Churchill D, Pillay D, Sabin C, Phillips A; UK Collaborative Group on HIV Drug Resistance; UK Collaborative HIV Cohort Study.

Antivir Ther. 2008;13(6):771-7.

PMID:
18839778
19.

What is the risk of mortality following diagnosis of multidrug-resistant HIV-1?

Grover D, Copas A, Green H, Edwards SG, Dunn DT, Sabin C, Phillips A, Allen E, Pillay D; UK Collaborative Group on HIV Drug Resistance and UK Collaborative HIV Cohort Study (UK CHIC).

J Antimicrob Chemother. 2008 Mar;61(3):705-13. doi: 10.1093/jac/dkm522. Epub 2008 Jan 25.

PMID:
18222956
20.

Rate of AIDS diseases or death in HIV-infected antiretroviral therapy-naive individuals with high CD4 cell count.

Phillips AN, Gazzard B, Gilson R, Easterbrook P, Johnson M, Walsh J, Leen C, Fisher M, Orkin C, Anderson J, Pillay D, Delpech V, Sabin C, Schwenk A, Dunn D, Gompels M, Hill T, Porter K, Babiker A; UK Collaborative HIV Cohort Study.

AIDS. 2007 Aug 20;21(13):1717-21.

PMID:
17690569

Supplemental Content

Loading ...
Support Center